OpenAI Leads $153-Million Round in Biossil

Biossil has raised $153 million in a funding round led by OpenAI, according to a report by The Globe and Mail. The company will use the capital to bring resuscitated drugs to market.

The deal signals that OpenAI's investment activity now extends beyond core artificial intelligence infrastructure into biotechnology. The lead position in a nine-figure life sciences round places the AI developer alongside traditional healthcare and growth investors as a direct backer of drug commercialization.

Biossil's strategy centers on resuscitated drugs — medicines that were shelved, deprioritized, or abandoned during earlier development and that the company seeks to revive and carry through to market. The $153-million infusion represents the capital required to move that pipeline from revival work into actual commercial availability, The Globe and Mail reports.

The round's size places it among the more substantial private biotech financings of the current cycle. A $153 million commitment, with OpenAI leading, gives Biossil the runway to fund the late-stage and commercialization work that revived drug candidates typically require: clinical follow-through, regulatory engagement, manufacturing scale-up, and market entry.

For OpenAI, the investment fits a broader pattern of deploying capital into applied-science companies where artificial intelligence can compress development timelines. Drug revival is one such category. Candidates that failed or stalled in earlier eras often did so for reasons that modern computational tools — better target validation, richer patient data, sharper trial design — can now address. A resuscitation model lets a company sidestep the earliest, riskiest discovery phase entirely and begin with molecules whose safety and biology are already partly characterized.

The Globe and Mail did not report additional terms of the round, including participating investors, the valuation assigned to Biossil, or the specific drug candidates the company intends to advance. The reported figure of $153 million and OpenAI's lead role are the confirmed deal terms.

The choice to fund commercialization rather than early research marks the stage of Biossil's pipeline. Money allocated "to bring resuscitated drugs to market" typically funds the final stretch: completing remaining clinical obligations, securing approvals, and building the commercial apparatus to sell the medicines. That is a costlier and more execution-dependent phase than discovery, and it is where revived programs most often stall for lack of capital.

The participation of OpenAI as lead investor also raises questions about the operational relationship between the two companies. Whether OpenAI's involvement is purely financial or includes technology partnership — for example, applying its models to patient stratification or trial design for the revived candidates — was not specified in the report.

The financing lands at a moment when large AI developers are sitting on substantial capital reserves and are increasingly deploying them directly into applied-science bets rather than confining themselves to chips, data centers, and model developers. Biotech, with its long timelines and data-heavy workflows, has become a natural adjacent category.

For Biossil, the immediate task is execution. The company now holds the capital to carry resuscitated drugs across the commercialization line; the value of the round will be judged by how many of those revived candidates actually reach patients and generate revenue. The next milestones to watch are the identity of the lead candidates, any regulatory filings that follow, and confirmation of the round's full investor roster and valuation.